Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma

The prognosis of patients with uveal melanoma is poor. Because of the limited efficacy of current treatments, new therapeutic strategies need to be developed. Because p53 mutations are uncommon in uveal melanoma, reactivation of p53 may be used to achieve tumor regression. We investigated the use of combination therapies for intraocular melanoma, based on the p53 activators Nutlin-3 and reactivation of p53 and induction of tumor cell apoptosis (RITA) and the topoisomerase I inhibitor Topotecan. Nutlin-3 treatment induced p53-dependent growth inhibition in human uveal melanoma cell lines. The sensitivity to Nutlin-3 of the investigated cell lines did not correlate with basal Hdm2 or Hdmx levels. Nutlin-3 synergized with RITA and Topotecan to induce apoptosis in uveal melanoma cell lines and short-term cultures. Drug synergy correlated with enhanced induction of p53–Ser46 phosphorylation, which was attenuated by ATM inhibition. Nutlin-3 and Topotecan also significantly delayed tumor growth in vivo in a murine B16F10 model for ocular melanoma. Combination treatment appeared to inhibit tumor growth slightly more efficient than either drug alone. Nutlin-3, RITA and Topotecan lead to comparable p53 activation and growth inhibition under normoxia and hypoxia. Treatment with Nutlin-3 or RITA had no effect on HIF-1α induction by hypoxia, whereas the combination of these two drugs did inhibit hypoxia-induced HIF-1α. Also Topotecan, alone or in combination with Nutlin-3, reduced HIF-1α protein levels, suggesting that a certain level of DNA damage response is required for p53-mediated downregulation of HIF-1α. In conclusion, combination treatments based on small-molecule-induced p53 activation may have clinical potential for uveal melanoma.

[1]  T. Holak,et al.  NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro , 2005, Nature Medicine.

[2]  Jason S. White,et al.  Irreversible chromosome damage accumulates rapidly in the absence of ATM kinase activity , 2008, Cell cycle.

[3]  Giulia Piaggio,et al.  Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis , 2002, Nature Cell Biology.

[4]  Ettore Appella,et al.  ATM Mediates Phosphorylation at Multiple p53 Sites, Including Ser46, in Response to Ionizing Radiation* , 2002, The Journal of Biological Chemistry.

[5]  M. Christmann,et al.  Topotecan Triggers Apoptosis in p53-Deficient Cells by Forcing Degradation of XIAP and Survivin Thereby Activating Caspase-3-Mediated Bid Cleavage , 2010, Journal of Pharmacology and Experimental Therapeutics.

[6]  G. Selivanova,et al.  HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. , 2009, Cancer research.

[7]  Hua Jiang,et al.  MCT-10-0471 Molecular Cancer apeutics linical Development A Inhibits Multiple Myeloma Cell Growth through Induction 53-Mediated Caspase-Dependent Apoptosis and ergistically Enhances Nutlin-Induced Ther otoxic Responses , 2010 .

[8]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[9]  L. Neckers,et al.  Stabilization of wild-type p53 by hypoxia-inducible factor 1α , 1998, Nature.

[10]  J. Yokota,et al.  Requirement of ATM for Rapid p53 Phosphorylation at Ser46 without Ser/Thr-Gln Sequences , 2010, Molecular and Cellular Biology.

[11]  M. Lerman,et al.  DNA Damage Is a Prerequisite for p53-Mediated Proteasomal Degradation of HIF-1α in Hypoxic Cells and Downregulation of the Hypoxia Marker Carbonic Anhydrase IX , 2004, Molecular and Cellular Biology.

[12]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[13]  L. Huang,et al.  Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. , 2009, Carcinogenesis.

[14]  Michael A. Dyer,et al.  Inactivation of the p53 pathway in retinoblastoma , 2006, Nature.

[15]  G. Stark,et al.  Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. , 2006, Cancer research.

[16]  Marina Konopleva,et al.  Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. , 2006, Blood.

[17]  J. Blaydes,et al.  The influence of cell context on the selection pressure for p53 mutation in human cancer. , 1998, Carcinogenesis.

[18]  M. Dewhirst,et al.  Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. , 2005, Cancer cell.

[19]  Baoli Hu,et al.  MDMX Overexpression Prevents p53 Activation by the MDM2 Inhibitor Nutlin* , 2006, Journal of Biological Chemistry.

[20]  L. Mayo,et al.  Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. , 2007, Cancer research.

[21]  J. Augsburger,et al.  Effectiveness of treatments for metastatic uveal melanoma. , 2009, American journal of ophthalmology.

[22]  Gabriel Pons,et al.  MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. , 2006, Blood.

[23]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[24]  Gary Box,et al.  Small-Molecule Activation of p53 Blocks Hypoxia-Inducible Factor 1α and Vascular Endothelial Growth Factor Expression In Vivo and Leads to Tumor Cell Apoptosis in Normoxia and Hypoxia , 2009, Molecular and Cellular Biology.

[25]  Da-Qing Yang,et al.  The ATM Inhibitor KU-55933 Suppresses Cell Proliferation and Induces Apoptosis by Blocking Akt In Cancer Cells with Overactivated Akt , 2010, Molecular Cancer Therapeutics.

[26]  E. Jordanova,et al.  In Aged Mice, Outgrowth of Intraocular Melanoma Depends on Proangiogenic M2-Type Macrophages , 2010, The Journal of Immunology.

[27]  E. Danen,et al.  Establishment and characterization of an uveal‐melanoma cell line , 1995, International journal of cancer.

[28]  T. Kivelä,et al.  Metastatic Uveal Melanoma , 2006, International ophthalmology clinics.

[29]  K. Sakaguchi,et al.  Phosphorylation of human p53 by p38 kinase coordinates N‐terminal phosphorylation and apoptosis in response to UV radiation , 1999, The EMBO journal.

[30]  Mengjia Tang,et al.  Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells* , 2006, Journal of Biological Chemistry.

[31]  M. Schutte,et al.  Role of Mdm4 in drug sensitivity of breast cancer cells , 2010, Oncogene.

[32]  L. Karnell,et al.  The National Cancer Data Base report on cutaneous and noncutaneous melanoma , 1998, Cancer.

[33]  G. Calin,et al.  Regulation of tumor angiogenesis by EZH2. , 2010, Cancer cell.

[34]  Galina Selivanova,et al.  MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. , 2009, Cancer cell.

[35]  M. Protopopova,et al.  Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.

[36]  L. Vassilev,et al.  MDM2 inhibitors for cancer therapy. , 2007, Trends in molecular medicine.

[37]  S. Berg,et al.  MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death , 2006, Molecular Cancer Therapeutics.